Notably, the role of RAS/BRAFV600E mutational status and the origin of DNA MMR system (Lynch syndrome vs. sporadic CRC) in the efficacy of ICIs for MSI-H/dMMR mCRC is  uncertain.2-5 For stage III colon patients with cancer receiving adjuvant FOLFOX, BRAF, or KRAS mutations are independently associated with shorter survival in those with microsatellite-stable colon cancer, but not MSI tumors.6,7 In mCRC, RAS/BRAFV600E mutations are well-known molecular modifiers of prognosis with an impact on anti-cancer therapies such as anti-EGFR targeted strategies. The gene discussed is KRAS; the disease is cancer.